ClinicalTrials.gg
RecruitingNCT06481592Updated Oct 30, 2025

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

A Phase 2 interventional study of Lifileucel in Endometrial Cancer, sponsored by Iovance Biotherapeutics, Inc.. Recruiting at 12 sites in United States. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-10-30.

Sponsored by Iovance Biotherapeutics, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 715 studies in Endometrial Neoplasms with a site in United States — 197 open to participants now, 287 under way, 22 of them phase 3. Endometrial Neoplasms · United States.

Planned enrollment
292nd of 591
60 · median 60
Started
2024
with 45 others
Phase 2
178 of 715
35 open now
Primary completion
2028-05
later than 192 of 286 live
Registered
593rd of 715
by date

Among the 715 studies in Endometrial Neoplasms with a site in United States, this one is the 292nd largest by planned enrollment of the 591 interventional ones that give a count, is one of 46 that started in 2024, is one of 178 in phase 2, reaches primary completion later than 192 of the 286 other live ones, and was the 593rd registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

197 of the 715 studies in Endometrial Neoplasms with a site in United States are open now. Recruiting first, the newest first:

192 more — sign in →

All 197 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 715 studies in Endometrial Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.

Read the detailed description

The study will enroll participants with advanced endometrial cancer who previously received treatment with platinum-based chemotherapy and an anti-programmed cell death protein-1 (PD-1)/programmed death ligand 1 (PD-L1) agent in a recurrent or advanced setting, either sequentially or in combination.

03

Conditions studied

  • Endometrial Cancer

Keywords

  • Tumor Infiltrating Lymphocytes
  • TIL
  • Endometrial Cancer
  • Endometrial
  • Cell Therapy
  • Cellular Immunotherapy
  • IL-2
  • Non-myeloablative lymphodepletion (NMALD)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must have a confirmed diagnosis of endometrial carcinoma. All histologies, including carcinosarcoma, will be allowed. Uterine sarcoma will not be allowed.
  2. Participants who have received the following previous therapies:

    • At least 1 but no more than 4 lines of prior systemic therapy with no more than 2 in any setting (ie, or adjuvant setting as well as for recurrent, , or primary unresectable disease. .
    • Participants have received platinum-based chemotherapy and /PD-L1 therapy.
    • Participants who declined platinum-based chemotherapy regimen and/or an anti-PD-1/PD-L1 therapy or were deemed ineligible for such therapies by the investigator may be considered after discussion with the medical monitor.
    • Systemic therapy counting towards lines of therapy includes chemotherapy, targeted therapy, immunotherapy, and antibody drug conjugates, given alone or in combination. Hormonal therapy does not count as a line of therapy.
    • Participants must have either (i) documented radiographic disease progression during or after the last line of therapy or (ii) discontinued their last line of therapy because of treatment intolerance or toxicity or (iii) with medical monitor discussion, participant/physician decision in the context of stable disease with evidence of tumor growth.
  3. Participants who have an (ECOG) performance status of 0 or 1 and estimated of >6 months.
  4. Participants having at least one resectable lesion and at least one , following resection of the lesion for TIL generation.
  5. Participants who have adequate organ function, including adequate cardiopulmonary function.
  6. Participants of must be willing to practice an approved method of highly effective during treatment and up to 12 months after the last dose of study intervention.
  7. Participants who are >70 years of age may be allowed to enroll after the investigator discusses with the medical monitor.

Exclusion criteria

Exclusion Criteria:

  1. Participants who have symptomatic untreated .
  2. Participants who have had a history of allogeneic organ transplant or any form of cell therapy involving prior conditioning chemotherapy within the past 20 years.
  3. Participants who require systemic therapy > 10 mg/day prednisone or another steroid equivalent dose.
  4. Participants who have any form of primary immunodeficiency.
  5. Participants who have another primary within the previous 3 years.
  6. Participants who have received or will receive a live or attenuated vaccination within 28 days prior to the start of the NMALD.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Patients with Endometrial Cancer

    Biological: Lifileucel

Interventions

  • BiologicalLifileucel

    A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, participant is infused with lifileucel, followed by IL-2.

    Also known as: Tumor-Infiltrating Lymphocytes, TIL

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    To evaluate the proportion of participants who have a confirmed complete response (CR) or partial response (PR) per RECIST v1.1.

    Time frame: Up to 5 Years

Secondary outcomes

  1. Complete Response Rate

    To evaluate the proportion of participants who have a confirmed complete response (CR) per RECIST v1.1.

    Time frame: Up to 5 Years

  2. Duration of Response

    To measure from the first time that criteria are met for complete response (CR) or partial response (PR) per RECIST v1.1.

    Time frame: Up to 5 Years

  3. Disease Control Rate

    To measure by the percentage of participants with best overall confirmed response of complete response (CR) or partial response (PR) at any time or stable disease (SD) for at least 4 weeks per RICIST v1.1.

    Time frame: Up to 5 Years

  4. Progression-Free Survival

    To evaluate the time from the date of the lifileucel infusion until disease progression per RECIST v1.1.

    Time frame: Up to 5 Years

  5. Overall Survival

    To measure the time from the date of lifileucel infusion to death due to any cause.

    Time frame: Up to 5 Years

  6. Adverse Events

    To characterize the safety and tolerability profile of lifileucel in participants with advanced endometrial cancer.

    Time frame: Up to 5 Years

07

Study locations

12 of 12 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for May 2028, 43 months after the start.

Of 139 phase 2 interventional studies under Endometrial Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 115. This study's planned 43 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2024
First posted
Jul 1, 2024
StartActual
Oct 29, 2024
Primary completionEst.
May 2028
CompletionEst.
Nov 2029
Last update
Oct 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06481592
Lead sponsor
Iovance Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Jul 1, 2024
Start date
Oct 29, 2024
Primary completion
May 2028 (estimated)
Completion
Nov 2029 (estimated)
Last update
Oct 30, 2025

Study contacts

Iovance Biotherapeutics Study Team
Contact
Clinical.Inquiries@iovance.com
1-844-845-4682
Iovance Biotherapeutics Study Team
study director · Iovance Biotherapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lifileucel

Start the discussion